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Introduction
Under certain conditions, pathogens like Yersinia secrete high
levels of proteins. This ability correlates with cytotoxicity and
virulence. The complete inactivity of the secreted proteins when
added directly to host cells stimulated research to disclose this
‘‘non-AB toxin mechanism’’ of virulence, and eventually led to the
discovery of the type III secretion mechanism and the ‘‘injection
model’’ for virulence effector targeting. Recent studies question
this model and suggest that the T3SS effector-targeting mecha-
nism may resemble the classical AB toxin delivery mechanism.
The Ca
2+ Paradox
Human pathogenic Yersinia species are uniquely dependent on
millimolar concentrations of Ca
2+ when grown at 37uC. This
phenotype is characterized by normal growth at 37uC in the
presence of Ca
2+, and growth restriction in Ca
2+-depleted medium
[1]. This unusual Ca
2+ requirement has been linked to the
presence of a virulence plasmid [2], originally discovered by Zink
et al. [3]. The plasmid encoded a set of proteins (Yersinia outer
proteins, or Yops) [4] that were secreted into the culture
supernatant in massive amounts during growth restriction in the
absence of Ca
2+ [5,6]. The coupling of the Yops to the virulence
plasmid indicated strongly that they were essential virulence
determinants. This hypothesis was further supported when
convalescence sera obtained from Yersinia-infected patients were
shown to contain antibodies recognizing the secreted Yop proteins
[4], leading to the hypothesis that low intracellular Ca
2+ inside
mammalian cells induced expression of the Yop virulon during
infection. The role of calcium was thus paradoxical as conditions
promoting Yop secretion resulted in growth restriction.
Polarized Translocation of Yop Effectors
Cavanaugh and Randall were the first to demonstrate that
blockage of phagocytosis is crucial for Yersinia to cause disease [7].
The significance of this finding was later strengthened by the
finding that the bacteria replicate predominantly at extracellular
sites during infection [8]. YopH and YopE were essential to the
ability to block phagocytosis [9]. These data demonstrated that
Yersinia is an extracellular pathogen and that Yop expression is a
prerequisite for virulence, and also raised the question of how the
pathogen was able to affect target cells from its extracellular
location—an especially intriguing question because, unlike AB
toxins, the addition of purified Yops to cultured cells did not cause
any obvious effects.
The first important discovery to resolve this issue was the
finding that microinjection of purified YopE into target cells
induced a cytotoxic response [10], demonstrating that YopE must
be translocated into target cells to elicit its biological function. It
was also concluded that in addition to YopE, the secreted protein
YopD was essential for the delivery of YopE across the target cell
membrane by infecting bacteria [10]. Confocal imaging and
biochemical fractionation were used to demonstrate that contact
between Yersinia and the target cell induces Yop expression
accompanied by the translocation of YopE into target cells
[11,12]. The majority of YopE was present in the target cell
cytosol and no YopE was detected in the culture medium,
indicating that Yop translocation was polarized and occurred only
at the zone of contact between the bacterium and the target cell
[12]. Translocation of Yop effectors into target cells was later
demonstrated by another approach using an elegant reporter
system [13].
Does the Type III Secretion System Function as a
Microsyringe?
Cornelis and co-workers were the first to demonstrate that the
virulence plasmid of pathogenic Yersinia encodes a dedicated Yop
secretion system [14]. Some genes identified by Cornelis et al. had
homologous counterparts in plant pathogens, and Reeves and
Salmond realized that these different pathogens exhibited a
common secretion pathway, dubbed ‘‘Type III secretion’’ (T3S)
[15]. An additional set of Yersinia genes was identified that
displayed remarkable homology to corresponding genes in
Salmonella and Shigella [16]. The idea that highly conserved
secretory systems could allow heterologous secretion was based
on these observations, and corroborated by experimental evidence
demonstrating that S. typhimurium secreted YopE via a T3SS-
dependent mechanism. Both secretion and cell contact-dependent
translocation of effectors into the target cells were functionally
conserved among yersiniae, salmonellae, and shigellae [17], which led
us to suggest that the T3SS-dependent secretion and translocation
of effector proteins were highly conserved among different
pathogens and occurred through a ‘‘microinjection mechanism.’’
That the T3SSs are organized into supra-molecular structures
known as needle complexes was first shown in S. typhimurium [18].
This structure, which is believed to be common to all T3SSs,
resembles a syringe with a base structure and a needle-like
protrusion extending from the surface of the pathogen. The entire
needle complex is traversed by a fine, hollow tube that may allow
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Due to the suggestive similarities between the needle complex and
a syringe, it has been generally accepted that the effectors travel
directly through the needle complex from the bacterial cytosol into
the lumen of the eukaryotic target cell. However, no experimental
results have been presented to demonstrate that the effectors are
secreted through the needle structure.
Are the Effectors Translocated through a Pore
Formed in the Host Cell Membrane?
The secreted substrates can be divided into two functional
classes: effectors are delivered into the target cell where they elicit
a biological response, while translocators facilitate the delivery of
effectors across the plasma membrane [10,12,13]. A key signature
of translocators is the putative membrane spanning domain(s),
which has some similarities to pore-forming toxins [20]. The first
translocator protein found to exhibit pore-forming and hemolytic
activities was Shigella IpaB [21]. Subsequently, the Yersinia
homologue YopB was found to be essential for Yop effector
translocation; similar to IpaB, YopB also induces erythrocyte
hemolysis [22,23]. The pore-forming ability of YopB correlates
with functional translocation, supporting the idea that the effectors
are delivered through a pore in the host cell membrane. Recent
work has revealed that LcrV (initially thought to be a translocator
protein) is localized at the tip of the needle complex [24]. LcrV has
also been proposed to be essential for insertion of the hydrophobic
translocators YopB and YopD into target cell membranes. These
properties of LcrV agree nicely with the ‘‘injection model.’’
However, all findings are not compatible with this model. For
example, Sasakawa and co-workers reported that the Shigella
translocators IpaB, IpaC, and IpaD are surface-localized before
target cell contact [25]. The majority of these proteins are rapidly
released after target cell contact is established, indicating that
Shigella senses target cell contact and responds accordingly.
Furthermore, latex beads coated with purified Ipa protein
complexes are internalized by target cells through a mechanism
that resembles the active, T3SS-dependent engulfment of Shigella
[26]. The apparent surface localization of these proteins before
target cell contact is difficult to reconcile with the injection model.
On the other hand, recent studies in Shigella demonstrating that
IpaB and subsequently IpaC are recruited to the tip of the needle
from its location at the bacterial surface in response to target cell
contact lend support to the injection model [27]. Nevertheless,
these results do not support the idea that the T3SS forms a conduit
that allows both translocators and effectors to be secreted in one
step by the same T3SS, since at least the translocators are secreted
to the surface before eukaryotic cell contact has been established.
Binary AB Toxin Revisited?
Recent attempts to visualize T3SS substrates during infection
using immunogold labeling and transmission electron microscopic
analysis revealed that the majority of Yop translocators and
effectors are present on the surface of the bacterium before target
cell contact [28]. This finding was surprising because the injection
model predicts that the T3SS substrates should be present in a
secretion competent conformation in the bacterial cytosol before
target cell contact. Remarkably, a yopH null mutant coated with
purified YopH was translocation competent and complemented
the mutant phenotype. The translocation of surface-localized
YopH and YopH-b-lactamase reporters is also T3SS dependent
and requires functional translocators, as well as a specific
translocation domain present in YopH. The N-terminal secretion
signal is redundant for translocation of externally added YopH,
demonstrating that secretion and translocation are two separate
events. Importantly, T3SS-dependent translocation of externally
added YopH has also been achieved in S. typhimurium, indicating
that the ability to translocate surface-localized effectors is
conserved among different T3SS-dependent pathogens. Taken
together, these data support a two-step model in which the T3SS
substrates are secreted first. After target cell sensing, these surface-
localized effectors are translocated across the target cell plasma
membrane (Figure 1). The translocation step could superficially be
compared to the delivery of binary AB toxins: the hydrophobic
T3SS translocators resemble the pore-forming B-moiety that
Figure 1. Proposed model for T3SS-dependent protein translocation by a binary AB toxin like mechanism. T3SS translocators (t) and
effectors (e) are secreted by the T3SS across the bacterial envelope (IM and OM) to the surface of the cell before host cell contact (1). Target cell
sensing results in release of the surface localized T3SS substrates (2). The translocators (t) assemble into a pore in the target cell plasma membrane
(PM) and mediate the translocation of the effectors (e) into the target cell cytoplasm (3).
doi:10.1371/journal.ppat.1002669.g001
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effectors). In this scenario, tight binding of the bacterium to the
target cell provides the micro-environment required for efficient
translocation of effectors across the plasma membrane. This
requires that the surface-localized T3SS substrates are released
when the bacterium senses target cell contact, leading to
derepression of the yop regulon via the T3SS [11]. Because
increased yop expression is coupled to increased Yop translocation,
release may be coupled to the needle complex. Therefore, we
suggest a sensory role for the needle complex, thereby explaining
the requirement for target cell contact in T3SS-dependent effector
delivery. However, our results do not exclude the injection model,
because it is still possible for the two processes to operate in
parallel. Obviously, more work is needed before the molecular
details of the translocation are resolved.
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